Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Durvalumab given IV at 1500 mg Q4W ±2 days

AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW

AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28

Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off

Olaparib (AZD2281) given orally at 300 mg BD

Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter

Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days

cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1

AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.

AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28

AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28

AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle